
Biohaven Ltd
BHVNHealthcare|Biotechnology|USA
$15.55
-1.24 (-7.39%)
Tangible Book
$0.73
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
null,
23.44,
93.17,
288.29,
791.71
],
"ebit_estimate": [
-478.29,
-445.12,
-358.44,
-311.25,
36.68
],
"ebitda_estimate": [
-429.76,
-406.26,
-436.55,
-497.65,
-161.3
],
"net_income_estimate": [
-452.15,
-421.47,
-391.03,
-309.43,
29.27
],
"per_share_eps_estimate": [
-3.09,
-2.5,
-1.89,
-1.37,
0.36
],
"eps_nri_estimate": [
-3.03,
-2.4,
-1.95,
-1.44,
0.28
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
-0.03,
-0.18,
-0.07,
0.51,
0.79
],
"pretax_income_estimate": [
-451.96,
-421.47,
-353.77,
-309.43,
38.37
],
"operating_cash_flow_per_share_estimate": [
-2.4,
-1.59,
-1.65,
-1.89,
-0.45
],
"roa_estimate": [
-116.3,
-146.35,
-148.65,
-76.7,
-7
],
"roe_estimate": [
-400.97,
-482.71,
-389.41,
-15.2,
-79.1
],
"gross_margin_estimate": [
85.5,
83.2,
88.33,
83.6,
85.9
],
"operating_cash_flow_estimate": [
-354.28,
-234.71,
-243.93,
-278.25,
-65.69
],
"pettm_estimate": [
0,
0,
0,
0,
42.72
],
"long_term_growth_rate_mean": 32.95,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 33.74,
"future_eps_nri_estimate_growth": 32.95,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 20.14,
"future_ebitda_estimate_growth": 14.67,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 17.79,
"future_pretax_income_estimate_growth": 20.17,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 33.66
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
0.49,
0.74,
0.98,
null,
null,
7.75,
13.08,
null
],
"ebit_estimate": [
-114.74,
-113.98,
-110.94,
-117.78,
-118.72,
-114.9,
-111.22,
null
],
"ebitda_estimate": [
-103.73,
-104.08,
-97.71,
null,
null,
null,
null,
null
],
"net_income_estimate": [
-112.35,
-111.09,
-107.16,
-115.52,
-116.66,
-112.87,
-108.71,
null
],
"per_share_eps_estimate": [
-0.77,
-0.72,
-0.67,
-0.7,
-0.7,
-0.69,
-0.68,
null
],
"eps_nri_estimate": [
-0.73,
-0.68,
-0.63,
-0.68,
-0.69,
-0.65,
-0.62,
-0.81
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-111.72,
-110.69,
-106.41,
-115.48,
-116.62,
-112.83,
-108.83,
null
],
"operating_cash_flow_per_share_estimate": [
-0.59,
-0.52,
-0.26,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
-388.5,
-177.36,
-98.83,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
221,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
-87.58,
-77.25,
-38.38,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null,
null
],
"long_term_growth_rate_mean": 32.95,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": 33.74,
"future_eps_nri_estimate_growth": 32.95,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 20.14,
"future_ebitda_estimate_growth": 14.67,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 17.79,
"future_pretax_income_estimate_growth": 20.17,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": 33.66
}